A Complete Guide to Finasteride in Hair Loss & Hair Transplantation | 100 FACTS

Main ideas / lessons conveyed

• Finasteride is presented as an evidence-based option for male pattern hair loss, primarily to stabilize hair loss and in some cases allow regrowth. It is not a cure and does not permanently eliminate the underlying genetic tendency.
• The speaker argues that most feared side effects are uncommon, often quoted around ~0.5–1%. Proper screening, counseling, and blood testing can identify patients more likely to experience problems.
• Risk–benefit framing: benefits can be substantial for many patients, but not everyone should take it. Suitability depends on personal factors such as:
  • age
  • balding severity
  • comorbidities
  • mental health
  • baseline sexual function
  • hormone status
• Dose flexibility/customization is emphasized (start low, adjust based on response and tolerability), but the speaker also argues against “one-size-fits-all.”
• Hair transplant context: after transplant, the speaker claims finasteride use is mandatory to maintain transplanted/retained hair, and that dose experimenting is not appropriate during the early post-op period.
• The talk compares finasteride vs. dutasteride:
  • dutasteride is described as more potent and possibly associated with different side-effect risk.
  • Minoxidil is mentioned as a treatment with a different mechanism.
• Stopping finasteride is framed as reversing the “masking/stabilization” effect, meaning shedding may occur and overall hair loss progression is expected to resume.
• A practice concept called “switch off / switch on” is introduced:
  • the speaker suggests periodic stopping may reduce perceived tissue-level accumulation and side-effect likelihood.
• Supplementation strategies when response wanes are suggested, including intermittent dutasteride (e.g., once weekly, per the speaker’s approach).
• Pregnancy safety / handling precautions are discussed, including concerns about semen exposure and timing for couples planning pregnancy.
• The speaker addresses myths, particularly regarding “permanent” sexual side effects after discontinuation, claiming tissue clearance occurs within ~60–90 days and that persistent symptoms are often misattributed.

---

Methodology / instructions (organized bullet points)

1) Patient selection and safety screening (before starting)

• Do intensive counseling to set expectations and reduce fear-driven discontinuation.
• Use blood tests to help assess risk and baseline hormone status (the talk later lists common markers).
• Avoid finasteride in certain risk groups, especially:
  • pre-existing erectile dysfunction
  • suicidal ideation / depression
  • significant liver problems
  • history of breast cancer in men
  • aggressive prostate cancer
  • allergy to 5-alpha-reductase inhibitors
  • women who are pregnant, planning pregnancy, or breastfeeding (with special handling precautions)

---

2) Dosing approach (general principles)

• Start at the minimal effective dose, then scale up only if needed for response and tolerance.
• The speaker claims the required dose varies due to:
  • individual metabolism
  • degree/aggressiveness of baldness
  • time course and responsiveness
• A common dosing range cited for many patients:
  • 0.5 to 1 mg daily
• After hair transplant:
  • 1 mg daily for 6 months is described as mandatory by the speaker.
  • The speaker argues that micro-dosing during this window has “no role” because early effects are considered critical for implanted hair survival.

---

3) Alternate / low-frequency dosing (and caution)

• Some doctors (described as controversial in the talk) advise reduced-frequency dosing such as:
  • 0.5 mg on Mondays / Wednesdays / Fridays
• The speaker critiques this by claiming it may not cover testosterone “spikes” over the weekend (implying a coverage gap).

---

4) “Switch off / switch on” strategy (the speaker’s practice)

• Claims finasteride builds up in tissue (with a long tissue half-life described).
• Protocol described:
  1. After continuous 3 months, stop finasteride for 15 days
  2. Purpose: wash out accumulated tissue levels and reduce side-effect likelihood
• The speaker later frames this as useful especially in long-term therapy.

---

5) When response wanes after years

• The speaker states that in up to ~40% of patients, efficacy may begin to wane after 2–5 years.
• Suggested adjustment:
  • add dutasteride once weekly (0.5 mg) to improve maintenance/regrowth, with the claim that tolerability is better due to intermittent use.

---

6) Handling testosterone / estrogen modulation if side effects occur

• Since finasteride is claimed to increase estrogen levels, the speaker suggests:
  • obtain baseline and follow-up labs (testosterone/estradiol and related markers)
  • consider an estrogen inhibitor (named as aromatase inhibitor / arimix), discussed as requiring careful medical supervision

---

7) Managing alcohol and timing (as described)

• The speaker states heavy alcohol (example: >60 ml whiskey) may reduce finasteride’s effects.
• If someone drinks regularly in the evenings, dosing may be moved to early morning.
• Timing with meals is claimed to have no major difference.

---

8) Smoking out non-responders and side-effect monitoring

• Early shedding is described as normal:
  • shedding often occurs around 1–2 months
  • benefits expected around 3 months
  • shedding is stated not to negate long-term benefit (per the speaker’s assertion)
• Response monitoring:
  • regular photos in consistent lighting/settings every 15–30 days
  • possible hair shaft diameter measurements before vs. after as a quantitative method

---

9) Pregnancy planning / contraception-like precautions for couples

• The speaker recommends:
  • the male partner should stop finasteride 60 days before pregnancy attempts
  • remain off it until the partner is pregnant (for “peace of mind,” as described)
  • avoid the pregnant partner handling finasteride and avoid exposure during breastfeeding
• Additional handling precautions mentioned:
  • Women should not handle finasteride and should avoid exposure until breastfeeding is complete
  • precautions related to crushed tablets and wet hands, due to potential handling/skin absorption risk

---

10) Blood tests mentioned (hormonal workup)

Common labs for baseline and monitoring listed in the talk:

• Total testosterone
• Free testosterone
• DHT levels
• Estradiol levels
• Free androgen index (noted as somewhat controversial in the talk)

---

Key concepts / comparisons emphasized

Mechanism of action

• Finasteride inhibits 5-alpha-reductase, reducing conversion of testosterone → DHT.
• DHT’s role is framed as central to male pattern hair loss:
  • finasteride is described as a barrier/protective shield, not a “gene cure.”
• Finasteride is described as stabilizing loss for most users, with declining stabilization percentage over years (numbers like ~86% at 1 year and ~65% by 5 years are cited, while emphasizing variability).

Finasteride vs. dutasteride

• Dutasteride is described as broader/more potent, blocking more isoenzymes and potentially leading to different side-effect risk.

Minoxidil vs. finasteride

• Minoxidil is described as a stimulant/vasodilator (different mechanism).
• Finasteride is described as a DHT blocker.

---

Speakers / sources featured (as mentioned)

Speaker(s)

• The channel’s narrator / doctor (name not provided in subtitles)
  • references personal experience, including taking finasteride and observing/performing hair transplant procedures (FUT and FUE)

Sources / organizations mentioned

• American Hair Loss Association (cited for statistics on finasteride benefits)
• Merck (referenced regarding lawsuits / “bad press” and Propecia labeling context)
• U.S. FDA (referenced regarding approvals and labeling)
• GSK (GlaxoSmithKline) (referenced as the manufacturer of dutasteride)
• NCBI / National Center for Biotechnology Information (referenced in relation to micro-dose claims)
• Endocrinologist / Andrologist (specialists referenced for evaluating hypogonadism)
• Japan and Korea (approval of glutathione mentioned in passing)

Specific public figure mentioned

• Donald Trump (mentioned as publicly stating he took finasteride for many years)